Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol adjunctive treatment for first episode psychosis
ACTRN12624001303538Phase 3Recruiting
- Sponsor
- Orygen
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cannabidiol, sponsored by Orygen. Started Apr 2026; status: recruiting.
02
Drugs
cannabidiol
Beyond the preview
Go deeper on ACTRN12624001303538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001303538.